Clinical efficacy and safety of tacrolimus ointment in patients with vitiligo

Journal of Dermatology

Volumn 38, Issue 11, 2011, Pages 1092-1094

  Juan, Du ^a   Qianxi, Xu ^a   Zhou, Chen ^a   Jianzhong, Zhang ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE FUROATE; TACROLIMUS;

ADVERSE OUTCOME; AGE DISTRIBUTION; CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FOLLICULITIS; FOLLOW UP; HUMAN; HYPERPIGMENTATION; LETTER; SKIN PIGMENTATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITILIGO;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; TACROLIMUS; VITILIGO; YOUNG ADULT;

EID: 80355133285     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.01124.x     Document Type: Letter

References (9)

1. Westerhof W, Nieuweboor-Krobotova L, Mulder PG, Glazenburg EJ,. Left-right comparison study of the combination of futicasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135: 1061-1066. (Pubitemid 29430496)
2. Kim SM, Lee HS, Hann SK,. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999; 38: 546-550. (Pubitemid 29331937)
3. Brown MD, Gupta AK, Ellis CN, Rocher LL, Voorheers JJ,. Therapy of dermatologic disease with cyclosporine A. Adv Dermatol 1989; 4: 3-27.
4. Smith DA, Tofte SJ, Hanifin JM,. Repigmentation of vitiligo with topical tacrolimus. J Dermatol 2002; 205: 301-303.
5. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB,. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-585. (Pubitemid 36576373)
6. Xu AE, Zhang DM, Wei XD, Huang B, Lu LJ,. Efficacy and safety of tacrolimus cream 0.1% in the treatment of vitiligo. Int J Dermatol 2009; 48: 86-90.
7. Grimes PE, Morris R, Avanisse-Aghajani E, Soriano T, Meraz M, Metzger A,. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52-61. (Pubitemid 38887475)
8. Dawid M, Veensalu M, Grassberger M, Wolff K,. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006; 4: 942-946. (Pubitemid 44671823)
9. Boone B, Ongenae K, Van Geel N, Vernijns S, De Keyser S, Naeyaert JM,. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007; 17: 55-61. (Pubitemid 46383222)